HIV Treatment Advances and Other Final HIV Research Updates from the 2019 IAS Conference on HIV Science
July 25, 2019
Advances in HIV treatment options and studies on HIV prevention for women and girls were among the highlights yesterday at the 10th International AIDS Society Conference on HIV Science (IAS 2019). On the third and final day of the conference, NIAID's Carl Dieffenbach, Ph.D., and Anne Rancourt joined HIV.gov for a Facebook Live session to discuss those studies, reflect on key meeting takeaways, and look ahead to research developments on the horizon.
July 24, 2019
HIV prevention research was in the spotlight yesterday at the second full day of presentations at the 10th International AIDS Society Conference on HIV Science (IAS 2019). NIAID's Carl Dieffenbach, Ph.D., and Anne Rancourt joined HIV.gov for a Facebook Live session to discuss research about an experimental implantable form of PrEP and other findings that inform HIV prevention and treatment interventions.
HIV Research Updates from NIH’s Dr. Carl Dieffenbach at the 10th IAS Conference on HIV Science (IAS 2019)
July 23, 2019
As the 10th International AIDS Society Conference on HIV Science, or IAS 2019, opened in Mexico City, HIV.gov hosted a Facebook Live session with NIAID's Carl Dieffenbach, Ph.D., about initial research presented there and what is in store. Dr. Dieffenbach spoke with his colleague Anne Rancourt. They previewed a topic to be discussed at the conference: what’s new in the HIV prevention landscape, including HIV vaccine research. They also discussed new findings presented on Monday about a potential association between the HIV treatment medication dolutegravir and birth defects.
July 23, 2019
How to end the HIV epidemic is a theme of many conversations and presentations at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. After delivering presentations on that topic, NIAID Director Dr. Anthony Fauci shared his thoughts with HIV.gov. He observed that we now have the HIV prevention and treatment tools that, if implemented properly and aggressively, could theoretically end the HIV epidemic. He also acknowledged that implementation is a key issue and that there is a need for continued innovation and research.
June 26, 2019
When countries began providing HIV treatment to all people diagnosed with the virus, regardless of their immune health, the proportion of people who started treatment within a month of enrolling in HIV care jumped sharply in some nations, a study has found.
June 05, 2019
As NHLBI, NIAID, the Office of AIDS Research, and other NIH components adapt to the changing epidemiology of HIV infection, we are working together to support a coordinated research agenda that will optimize the health of people with HIV and improve their quality of life by reducing HIV-related co-morbidities. This year, on HIV Long-Term Survivors Day, we renew our commitment to study HIV disease across the lifespan.
May 29, 2019
Researchers launched the Randomized Trial to Prevent Vascular Events in HIV, or REPRIEVE, in 2015 with support from NIAID and the National Heart, Lung and Blood Institute. The ambitious trial is testing the ability of a statin medication to reduce the risk of heart disease in men and women with HIV. Researchers completed the enrollment phase of the trial earlier this year, welcoming more than 7,500 participants in eleven countries. REPRIEVE investigators and NIAID collaborators discussed the design and goals of the trial in the June issue of the American Heart Journal.
May 22, 2019
At the National Institute of Allergy and Infectious Diseases, we are proud of our legacy in HIV research, and we look for every opportunity to strengthen the ways we and our partners conduct clinical research and ensure that the trials we sponsor meet our regulatory responsibilities. Last year, the NIAID Division of AIDS initiated a mock inspection to evaluate the processes and systems associated with our clinical trial operations.
May 13, 2019
The National Institute of General Medical Sciences (NIGMS) has a rich history of fostering fundamental HIV research. Recently, NIGMS leadership had the strategic insight that this portfolio should be combined with the existing basic research program at NIAID to maximize collaboration and better leverage existing resources. NIGMS has excelled in fostering this research for 37 years, and we are honored to welcome their researchers into our scientific community.
HIV-Related Immune Activation May Predict Weight Gain and Exacerbate Complications, Especially in Women
March 06, 2019
Even when HIV is well-controlled with antiretroviral therapy, the virus can cause persistent immune activation that contributes to an increased risk of complications such as heart disease and certain cancers. New NIAID-supported research presented today at CROI 2019 in Seattle sheds light on the relationship between immune activation and weight gain.
March 06, 2019
As the first full day of presentations at the 2019 Conference on Retroviruses and Opportunistic Infections began to wrap up, HIV.gov spoke with NIAID's Dr. Carl Dieffenbach about some of the new HIV research highlights presented, including the case of a patient reported to be possibly cured of HIV infection. They also discussed the promising findings from a large study evaluating a “universal test and treat” strategy, as well as other results showing improved viral suppression and retention in care when point-of-care viral load testing is offered.
March 05, 2019
Rarely, people living with HIV are unable to maintain an undetectable viral load despite strict adherence to antiretroviral therapy (ART). NIAID-funded research suggests that this sometimes can occur when a single cell from the HIV reservoir—the population of long-lived HIV-infected cells that ART cannot eradicate—multiplies to create many identical cells that produce enough virus to be detected by standard viral load tests.
March 05, 2019
HIV.gov kicked off coverage of the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) with an interview with NIAID's Dr. Carl Dieffenbach just hours before the conference opened in Seattle. Dr. Dieffenbach spoke with his colleague Anne Rancourt about some of the current issues in the field of HIV research as well as what he is looking forward to learning more about at this year’s conference of HIV researchers from around the globe.
March 05, 2019
NIAID Director Anthony S. Fauci, M.D., addressed the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) last night about Ending the HIV Epidemic: A Plan for America and the role HIV research will play in it. HIV.gov spoke with Dr. Fauci ahead of his remarks at the opening plenary session of the conference.
What Will It Take to Reach “an HIV-Free Future”? Experts Discuss Progress for Smithsonian’s Outbreak Series
January 29, 2019
In observance of World AIDS Day, HIV experts discussed the future of the epidemic with community members at the Smithsonian’s National Museum of Natural History in Washington, D.C. Co-hosted by the American Society for Microbiology, “Imagining an HIV-Free Future” was one in a series of programs related to the new exhibition, Outbreak: Epidemics in a Connected World.
January 23, 2019
The safety and dosing requirements of a new drug licensed for use by nonpregnant adults may differ for pregnant women. This has been the case for drugs for treating both HIV and tuberculosis (TB), the most common HIV co-infection. An NIH study into how pregnancy affects the body’s processing of drugs for HIV and TB has helped provide a foundation for national and international HIV treatment guidelines for women who are pregnant or have recently given birth.
January 17, 2019
HIV is a master of sneaking past our natural defenses. Typically, when the body encounters a harmful virus, immune cells recognize viral proteins and stimulate the production of antibodies. HIV, however, has evolved several ways to cloak vulnerable areas of viral proteins. A report released last month from NIAID scientists reveals new insights into one such tactic of immune invisibility.
January 07, 2019
Scientists have previously recognized that the HIV reservoir varies in size between individuals. Now, NIAID researchers and their collaborators have discovered that variations in an important viral gene may play a role in the size of one’s HIV reservoir. Their findings, reported online last week, expand scientists’ understanding of how specific attributes of the virus a person acquires can affect the course and nature of their HIV infection.
January 03, 2019
NIAID’s HIV/AIDS Flickr album features a collection of downloadable HIV-related images, including infographics, microscopy images, photographs of HIV researchers and molecular models. These images are public domain and can be freely re-used. Please credit the National Institute of Allergy and Infectious Diseases.
October 25, 2018
At this week's HIV Research for Prevention (HIV R4P) conference in Madrid, scientists have reported progress in numerous areas of HIV prevention research. NIAID-supported scientists highlighted the need to expand HIV prevention and treatment services among populations greatly affected by HIV, described early findings from a study assessing the safety of a vaginal ring containing both an anti-HIV drug and a birth-control agent, and reported the added benefits of an intervention designed to facilitate treatment for HIV and injection drug use.
October 23, 2018
A durable end to the HIV/AIDS pandemic will require the development and widespread implementation of new and improved HIV prevention tools, according to NIAID Director Anthony S. Fauci, M.D. Yesterday, Dr. Fauci delivered a plenary lecture at the opening session of the HIV Research for Prevention (HIV R4P) conference, which is taking place this week in Madrid.
September 13, 2018
Some people treated with antiretroviral therapy after HIV has already significantly damaged the immune system may develop a serious condition called HIV-associated immune reconstitution syndrome, or IRIS. Now, researchers from NIAID and the NIH Clinical Center are working together to visualize and predict this common complication of HIV in a new way—with positron emission tomography, or PET.
July 30, 2018
The gut microbiome—the community of bacteria and other microbes naturally present in the gastrointestinal tract—plays a critical role in human health. NIAID Now spoke with senior investigator Jason Brenchley, Ph.D., about the link between the gut microbiome and HIV infection, and his lab’s recent research findings.
July 27, 2018
HIV.gov wrapped up their series of conversations with NIAID's Carl Dieffenbach, Ph.D., about scientific highlights from the 22nd International AIDS Conference (AIDS 2018) as the conference began to wind down.
July 25, 2018
As part of HIV.gov's series of Facebook Live dispatches from the 22nd International AIDS Conference in Amsterdam, Carl Dieffenbach, Ph.D., shared highlights from the conference's second full day of HIV research presentations.